Biscayne Pharmaceuticals Inc. is developing novel therapies that are based on proprietary growth hormone-releasing hormone (GHRH) technology discovered by Dr. Andrew V. Schally, a Nobel laureate and pioneering developer of blockbuster endocrine drugs. Biscayne’s GHRH analogs are expected to have broad applicability for the treatment of many different cancers and utility in heart disease, Alzheimer’s disease and diabetes.